Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Nicolaas Schaap"'
Autor:
Johannes Schetelig, Henning Baldauf, Linda Koster, Michelle Kuxhausen, Falk Heidenreich, Liesbeth C. de Wreede, Stephen Spellman, Michel van Gelder, Benedetto Bruno, Francesco Onida, Vinzenz Lange, Carolin Massalski, Victoria Potter, Per Ljungman, Nicolaas Schaap, Patrick Hayden, Stephanie J. Lee, Nicolaus Kröger, Kathy Hsu, Alexander H. Schmidt, Ibrahim Yakoub-Agha, Marie Robin
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/98cab44b6dfb4751a6cc5d0063c00727
Autor:
Johannes Schetelig, Henning Baldauf, Linda Koster, Michelle Kuxhausen, Falk Heidenreich, Liesbeth C. de Wreede, Stephen Spellman, Michel van Gelder, Benedetto Bruno, Francesco Onida, Vinzenz Lange, Carolin Massalski, Victoria Potter, Per Ljungman, Nicolaas Schaap, Patrick Hayden, Stephanie J. Lee, Nicolaus Kröger, Kathy Hsu, Alexander H. Schmidt, Ibrahim Yakoub-Agha, Marie Robin
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Results from registry studies suggest that harnessing Natural Killer (NK) cell reactivity mediated through Killer cell Immunoglobulin-like Receptors (KIR) could reduce the risk of relapse after allogeneic Hematopoietic Cell Transplantation (HCT). Sev
Externí odkaz:
https://doaj.org/article/693c028224f942ae8e114564d060c6a0
Autor:
Pavel Jindra, Depei Wu, Rama Al Hamed, Paolo Bernasconi, Manos Nikolousis, Michael Loschi, Arnon Nagler, Abdul Hamid Bazarbachi, Selim Corbacioglu, Montserrat Rovira, Virginie Gandemer, Mohamad Mohty, Matteo Pelosini, Hélène Labussière, Zinaida Peric, John A. Snowden, Wilfried Schroyens, Fabio Ciceri, Bipin N. Savani, Kazimierz Hałaburda, Nicolaas Schaap, Lucía López-Corral, Frédéric Baron, Xavier Poiré, Myriam Labopin, Enric Carreras, Blandine Guffroy, Sylvain Chantepie, Ali Bazarbachi
Publikováno v:
Bone Marrow Transplantation, 56, 917-927
Bone Marrow Transplantation, 56, 4, pp. 917-927
Bone marrow transplantation, Vol. 56, no.4, p. 917-927 (2021)
Bone marrow transplantation
Bone Marrow Transplantation, 56, 4, pp. 917-927
Bone marrow transplantation, Vol. 56, no.4, p. 917-927 (2021)
Bone marrow transplantation
Contains fulltext : 245127.pdf (Publisher’s version ) (Closed access) Allogeneic hematopoietic cell transplantation (alloHCT) is a complex, potentially fatal therapy featuring a myriad of complications. Triggering event(s) of such complications var
Autor:
Paolo Corradini, Gerald Wulf, Christopher P. Fox, Lutz P. Müller, Nicolaus Kröger, Nadira Duraković, Michel van Gelder, Nicolaas Schaap, Jan J. Cornelissen, Peter Dreger, Mohamad Sobh, Christof Scheid, Hélène Schoemans, Paul Browne, Linda Koster, Jennifer Hoek, Mauricette Michallet, Silvia Montoto, William Krüger, Ariane Boumendil, Wolfgang Bethge, Jakob Passweg, Johannes Schetelig, Domenico Russo
Publikováno v:
Bone Marrow Transplantation, 55, 884-890
Bone Marrow Transplantation, 55(5), 884-890. Nature Publishing Group
Bone Marrow Transplantation, 55, 5, pp. 884-890
Bone Marrow Transplantation, 55(5), 884-890. Nature Publishing Group
Bone Marrow Transplantation, 55, 5, pp. 884-890
Contains fulltext : 220662.pdf (Publisher’s version ) (Closed access) The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%
Autor:
Grzegorz W. Basak, Jiri Mayer, Soledad González Muñiz, Paul Bosman, Giulia Sbianchi, Johan Lund, Jane F. Apperley, Guido Kobbe, Stig Lenhoff, Sarah Lawless, Curly Morris, Cecilia Isaksson, Esa Jantunen, Achilles Anagnostopoulos, Paul Browne, Jennifer Byrne, Didier Blaise, Simona Iacobelli, Alessandro Rambaldi, Ibrahim Yakoub-Agha, Péter Reményi, Nicolaas Schaap, Keith M.O. Wilson, Stefan Schönland, Nicolaus Kröger, Christof Scheid, Cyrille Touzeau, Laurent Garderet
Publikováno v:
Clinical Lymphoma Myeloma & Leukemia, 21, 686-693
Clinical Lymphoma, Myeloma and Leukemia, 21(10), 686-693. CIG MEDIA GROUP, LP
Clinical Lymphoma Myeloma & Leukemia, 21, 10, pp. 686-693
Clinical Lymphoma, Myeloma and Leukemia, 21(10), 686-693. CIG MEDIA GROUP, LP
Clinical Lymphoma Myeloma & Leukemia, 21, 10, pp. 686-693
The rare myelomas, immunoglobulin (Ig)D, IgM, and non-secretory, have been associated with poorer outcomes following treatment than the common myelomas (IgG, IgA, and light-chain only). We show that even with "novel" therapies, augmented with autolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c144cc4a414ce17f2a367c91656e25de
https://hdl.handle.net/1887/3281911
https://hdl.handle.net/1887/3281911
Autor:
Mutlu Arat, Jenny Byrne, Ibrahim Yakoub-Agha, Sascha Dietrich, Johanna Tischer, Federica Sorà, Nicolaas Schaap, Eleni Tholouli, Francis Ayuk, Joan Hendrik Veelken, Yves Chalandon, Yener Koc, Henric Jan Blok, Johan Maertens, Per Ljungman, Maija Itälä-Remes, Jürgen Finke, Pavel Jindra, Jiri Mayer, Michael Stadler, Gérard Socié, Vanderson Rocha, Jakob Passweg, Arnon Nagler, Nicolaus Kröger, Aleksandar Radujkovic
Publikováno v:
Biology of Blood and Marrow Transplantation, 25, 10, pp. 2008-2016
Biology of Blood and Marrow Transplantation, Vol. 25, No 10 (2019) pp. 2008-2016
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 25, 2008-2016
Biology of Blood and Marrow Transplantation, 25(10), 2008-2016. ELSEVIER SCIENCE INC
Biology of Blood and Marrow Transplantation, Vol. 25, No 10 (2019) pp. 2008-2016
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 25, 2008-2016
Biology of Blood and Marrow Transplantation, 25(10), 2008-2016. ELSEVIER SCIENCE INC
The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a
Autor:
Gloria Tridello, Didier Blaise, Patrice Chevallier, Grzegorz W. Basak, Eric Deconinck, Jan Styczyński, Nicolaus Kröger, Diana Averbuch, Ibrahim Yakoub-Agha, Silvia Montoto, Nicolaas Schaap, Edouard Forcade, Rafael de la Cámara, Nina Knelange, Stephanie Nguyen-Quoc, Jakob Passweg, Catherine Cordonnier, Lidia Gil, Jan J. Cornelissen, Mauricette Michallet, Simone Cesaro, Katherine N. Ward, Nigel H. Russell, Gérard Socié, Eefke Petersen, Per Ljungman, Hendrik Veelken, Nathalie Fegueux, Peter Bader, Malgorzata Mikulska, Johan Maertens
Publikováno v:
Bone Marrow Transplantation, 54(12), 2060-2071. Nature Publishing Group
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients
Autor:
Myriam Labopin, Eefke Petersen, Jürgen Finke, Mohamad Mohty, Christoph Schmid, Donald Bunjes, Jan J. Cornelissen, Dietrich W. Beelen, Tobias Gedde-Dahl, Bipin N. Savani, Arnon Nagler, Nicolaus Kröger, Nicolaas Schaap, Montserrat Rovira, Johanna Waidhauser, Gwendolyn Van Gorkom, Jordi Esteve
Publikováno v:
Bone Marrow Transplantation, 56, 2445-2453
Bone Marrow Transplantation, 56(10), 2445-2453. Nature Publishing Group
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, ⟨10.1038/s41409-021-01322-w⟩
Bone Marrow Transplantation, 56, 10, pp. 2445-2453
Bone Marrow Transplantation, Nature Publishing Group, 2021, ⟨10.1038/s41409-021-01322-w⟩
Bone Marrow Transplantation, 56(10), 2445-2453. Nature Publishing Group
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, ⟨10.1038/s41409-021-01322-w⟩
Bone Marrow Transplantation, 56, 10, pp. 2445-2453
Bone Marrow Transplantation, Nature Publishing Group, 2021, ⟨10.1038/s41409-021-01322-w⟩
Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb9bd24eca641c014554135ee74ff3b
http://hdl.handle.net/2066/243910
http://hdl.handle.net/2066/243910
Autor:
Dietrich W. Beelen, Nicola Di Renzo, Nicolaas Schaap, Katja Sockel, Peter A. von dem Borne, Patrick Hayden, Zeynep Arzu Yegin, Jakob Passweg, Giulia Sbianchi, Elena V. Morozova, Marie-Thérèse Rubio, Nicolaus Kröger, Francesca Patriarca, Christine Wolschke, Ibrahim Yakoub-Agha, Donal McLornan, Paolo Bernasconi, Johannes Clausen, Tiarlan Sirait, Marie Robin, Jürgen Finke, Radovan Vrhovac, Grzegorz Helbig, Eibhlin Conneally, Wilfried Schroyens, Yves Beguin
Publikováno v:
Leukemia
Leukemia, 35, 3551-3560. SPRINGERNATURE
Leukemia, 2021, 35 (12), pp.3551-3560. ⟨10.1038/s41375-021-01276-4⟩
Leukemia, 35, 12, pp. 3551-3560
Leukemia, 35, 3551-3560
Leukemia, 35, 3551-3560. SPRINGERNATURE
Leukemia, 2021, 35 (12), pp.3551-3560. ⟨10.1038/s41375-021-01276-4⟩
Leukemia, 35, 12, pp. 3551-3560
Leukemia, 35, 3551-3560
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212303e866b3dd2753322399dfbf4659
https://www.ncbi.nlm.nih.gov/pubmed/34023851
https://www.ncbi.nlm.nih.gov/pubmed/34023851
Autor:
Michael Potter, Meral Beksac, Patrick Hayden, Uwe Platzbecker, Stephanie Nguyen-Quoc, Linda Koster, William Arcese, Alida Dominietto, Nicolaas Schaap, Monique C. Minnema, Edouard Forcade, Dirk Jan Eikema, Johanna Tischer, Virginie Gandemer, Ibrahim Yakoub-Agha, Hermann Einsele, Nicolaus Kröger, Angelo Michele Carella, Liesbeth C. de Wreede, Fabio Ciceri, Per Ljungman, Joan Hendrik Veelken, Jacob Passweg, Laure Vincent, Arancha Bermúdez, Adrian Bloor, Stefan Schönland, Attilio Olivieri
Publikováno v:
Bone Marrow Transplantation, 56, 2367-2381
Bone Marrow Transplantation, 56, 10, pp. 2367-2381
Bone Marrow Transplantation, 56(10), 2367-2381. SPRINGERNATURE
Bone Marrow Transplantation
Bone Marrow Transplantation, 56, 10, pp. 2367-2381
Bone Marrow Transplantation, 56(10), 2367-2381. SPRINGERNATURE
Bone Marrow Transplantation
The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::576c8e78782023de844351453f89f092
http://hdl.handle.net/2066/244085
http://hdl.handle.net/2066/244085